Biotechnology

Basecamp Research secures $140m for AI-driven therapies

UK-based Basecamp Research has secured $140m in a Series C funding round to train a new generation of its EDEN biological foundation models and advance AI-designed therapies towards clinical development.

BoomRay and Novartis Pharma sign $900m deal for radioligand therapy

China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.

Boehringer and Envisagenics to develop precision cancer therapies

Boehringer Ingelheim and Envisagenics have entered a research collaboration and option agreement that aims to validate tumour-specific targets for the development of precision therapies in solid tumours.

Sandoz and mAbxience agree on emicizumab biosimilar partnership

Sandoz and mAbxience have signed a licensing, development, manufacturing and commercialisation agreement covering a proposed emicizumab biosimilar candidate for haemophilia A.

Ona Therapeutics to develop ADC with WuXi’s payload-linker platform

WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.

Cellares and GenomeFrontier to assess automated GF-CART01 production

Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, on the Cell Shuttle platform.

Exegenesis Bio and Modalis sign research deal for Duchenne therapy

Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).

ABEC to expand global manufacturing network with new Wilson facility

ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process equipment and consumables.

Solstice Oncology secures $225m to drive porustobart’s development for cancer

Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.